BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 14, 2021
View Archived Issues
Overcoming EGFR-targeted TKI lung cancer resistance
Read More
Sulfopin, a new selective Pin1 inhibitor with in vivo anticancer activity in Myc-driven tumors
Read More
Engineered microbial therapy for local metabolic modulation of the tumor microenvironment
Read More
AMPK is a therapeutic target in PDAC
Read More
BDNF and NSE as biomarkers in alcohol use disorder and mood disorder comorbidity
Read More
New EGFR inhibitors identified at PharmaBlock Sciences
Read More
Heptares Therapeutics describes new GLP-1 and GLP-2 receptor agonists
Read More
LG Chem discovers GLP-1 receptor agonists
Read More
Beijing Jacobio Pharmaceuticals patents KRAS mutant protein inhibitors
Read More
New adenosine receptor antagonists synthesized at Exelixis
Read More
Suicide attempters with schizophrenia show increased serum S-100B protein levels
Read More
CD38 as therapeutic target for protection against doxorubicin-induced cardiotoxicity
Read More
Ikena Oncology targets TEAD transcription in cancer with IK-930
Read More
BNIP3L is a molecular target in mitophagy defects and mitochondrial dysfunction
Read More
SparingVision and Intellia Therapeutics establish strategic collaboration for ocular diseases
Read More
Titan Pharmaceuticals and MUSC enter research agreement on kappa-opioid receptor agonists
Read More
Immusoft and Takeda to jointly develop cell therapies for neurometabolic disorders
Read More
Preclinical studies show potential of melanocortin agonists PL-8331 and PL-9654 for ocular diseases
Read More